Pharmaceutical GMP Readiness in Japan
Japan's drug framework is set by the Pharmaceuticals and Medical Devices Act (PMD Act / Act No.
In Short
- MHLW (Ministry of Health, Labour and Welfare) sets policy; PMDA (Pharmaceuticals and Medical Devices Agency) reviews approvals and inspects.
- Each marketed drug needs a Japanese MAH holding a Type 1/2 marketing business licence.
- Master Files (MFs) can be filed by foreign manufacturers to protect proprietary content from the MAH while still supporting the dossier.
145, formerly PAL). MHLW issues policy and approvals; PMDA conducts scientific review and GMP inspections. Japan-GMP (the Ministerial Ordinance on GMP for Drugs and Quasi-drugs, MHLW Ord. 179/2004 as amended) is harmonized with PIC/S since Japan's PIC/S accession in 2014. Marketing requires a Marketing Authorization Holder (MAH) established in Japan; foreign manufacturers register as Accredited Foreign Manufacturers (AFM). This guide covers the Japan-specific layer over an ICH Q10 PQS.
Regulator and Legal Basis
MHLW (Ministry of Health, Labour and Welfare) sets policy; PMDA (Pharmaceuticals and Medical Devices Agency) reviews approvals and inspects. Statutes: PMD Act + GMP Ordinance.
More on regulator and Legal Basis
Japan is a PIC/S member and ICH founding regulator; J-GMP aligns closely with EudraLex Vol 4 but uses Japan-specific terminology and documentation expectations.
MAH, AFM, and the three-officer model
Each marketed drug needs a Japanese MAH holding a Type 1/2 marketing business licence. Every MAH must appoint three statutory officers: a General Marketing Compliance Officer, a Quality Assurance Officer, and a Safety Management Officer — each personally accountable.
More on mAH, AFM, and the three-officer model
Foreign manufacturing sites must be registered as AFMs before product approval; PMDA performs on-site or paper GMP inspections of AFMs.
Documentation, Language, and Translation
Master Files (MFs) can be filed by foreign manufacturers to protect proprietary content from the MAH while still supporting the dossier. Submissions are in Japanese; PMDA accepts English supporting data but key approval documents must be translated.
More on documentation, Language, and Translation
SOPs at AFMs do not need to be in Japanese but key records reviewed at inspection are commonly translated for the inspector.
Inspection Style and Common Findings
PMDA inspections are thorough and document-driven; expect detailed review of validation, change control, OOS handling, and supplier qualification. Findings are classified and reported in the inspection report; serious findings can delay approval.
More on inspection Style and Common Findings
The EU–Japan MRA covers human medicines for routine GMP inspections; PMDA still inspects AFMs at approval time for new applications.
A 90–180 day Japan readiness path
- Days 0–30
appoint MAH, register AFM, name the three statutory officers.
- Days 31–90
align documentation to J-GMP; prepare bilingual SOP summaries; ensure Annex 1 / Annex 11 / GAMP 5 alignment.
- Days 91–180
pre-inspection self-audit, then host PMDA inspection.
Questions
Can a foreign company act as its own MAH?
No — the MAH must be established in Japan with the three statutory officers. Foreign manufacturers typically partner with a local MAH or stand up a Japanese subsidiary.
Does the EU–Japan MRA waive PMDA inspection?
It covers routine surveillance GMP inspections for human medicines, reducing duplicate on-site visits between PMDA and EU authorities. New-product approval inspections are typically still performed by PMDA.
What is a Master File (MF) and when should we file one?
An MF is a confidential filing by an API or component manufacturer that supports the MAH's drug dossier without disclosing proprietary detail to the MAH. File an MF when the proprietary content (synthesis, source) must be protected while still supporting Japanese approval.
Practical orientation, not legal advice. Rules differ by jurisdiction; your quality and compliance team decides what applies.
The Pharmaceutical Operations Guide
Right material. Right record. Released by a person.
- Who decides, and who may not
- Supplier to finished bulk
- Test, review, investigate
- Packs, serialisation and recall
Plus Evidence map and four worksheets.
Get the pharmaceutical guideWe ask for your name and email so we can handle this request. The full guide then opens on this site, ready to translate, print or save. Privacy policy. Practical orientation, not legal advice; your quality unit decides which rules apply.
UltimateFree guide
The Pharmaceutical Operations Guide
Right material. Right record. Released by a person.
Keep reading
Global Pharmaceutical GMP Readiness: Principles That Travel- Australia Pharmaceutical GMP Readiness: TGA and PIC/S GMP
Brazil Pharmaceutical GMP Readiness: ANVISA RDC 658/2022
Canada Drug GMP Readiness: Food and Drug Regulations Part C, Division 2
China Pharmaceutical GMP Readiness: NMPA and China GMP
EU GMP Guide: EudraLex Volume 4 Chapters, Annexes and Who Decides